JP2008539267A5 - - Google Patents

Download PDF

Info

Publication number
JP2008539267A5
JP2008539267A5 JP2008509128A JP2008509128A JP2008539267A5 JP 2008539267 A5 JP2008539267 A5 JP 2008539267A5 JP 2008509128 A JP2008509128 A JP 2008509128A JP 2008509128 A JP2008509128 A JP 2008509128A JP 2008539267 A5 JP2008539267 A5 JP 2008539267A5
Authority
JP
Japan
Prior art keywords
compound according
och
formula
carbon
attached form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008509128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008539267A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/016057 external-priority patent/WO2006116614A1/en
Publication of JP2008539267A publication Critical patent/JP2008539267A/ja
Publication of JP2008539267A5 publication Critical patent/JP2008539267A5/ja
Pending legal-status Critical Current

Links

JP2008509128A 2005-04-26 2006-04-26 ベンズイソオキサゾールピペリジン化合物及びその使用方法 Pending JP2008539267A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67520205P 2005-04-26 2005-04-26
PCT/US2006/016057 WO2006116614A1 (en) 2005-04-26 2006-04-26 Benzisoxazole piperidine compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2008539267A JP2008539267A (ja) 2008-11-13
JP2008539267A5 true JP2008539267A5 (enExample) 2012-12-06

Family

ID=36754209

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008509129A Expired - Fee Related JP5049267B2 (ja) 2005-04-26 2006-04-26 ベンズイソオキサゾールピペラジン化合物およびその使用方法
JP2008509128A Pending JP2008539267A (ja) 2005-04-26 2006-04-26 ベンズイソオキサゾールピペリジン化合物及びその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008509129A Expired - Fee Related JP5049267B2 (ja) 2005-04-26 2006-04-26 ベンズイソオキサゾールピペラジン化合物およびその使用方法

Country Status (15)

Country Link
US (3) US7494998B2 (enExample)
EP (2) EP1877405B1 (enExample)
JP (2) JP5049267B2 (enExample)
CN (1) CN101208314B (enExample)
AT (2) ATE461925T1 (enExample)
AU (1) AU2006239302B2 (enExample)
CA (2) CA2606473C (enExample)
CY (1) CY1110026T1 (enExample)
DE (2) DE602006013115D1 (enExample)
DK (1) DK1877390T3 (enExample)
ES (2) ES2341127T3 (enExample)
MX (1) MX2007013352A (enExample)
PL (1) PL1877390T3 (enExample)
PT (1) PT1877390E (enExample)
WO (1) WO2006116614A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
CN101208314B (zh) * 2005-04-26 2010-12-08 海普尼昂公司 苯并异*唑哌嗪化合物及其使用方法
USRE45336E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
NZ594353A (en) 2006-05-18 2013-02-22 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
US8148418B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
CN104069567A (zh) * 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
EP2136863A2 (en) * 2007-03-19 2009-12-30 Insuline Medical Ltd. Device for drug delivery and associated connections thereto
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体
EP2231229A1 (en) 2007-12-18 2010-09-29 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20090263449A1 (en) * 2008-04-09 2009-10-22 Surmodics, Inc. Delivery of nucleic acid complexes from materials including negatively charged groups
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
HRP20180589T1 (hr) 2008-10-28 2018-05-18 Arena Pharmaceuticals, Inc. Pripravci modulatora serotoninskog receptora 5-ht2a koji su korisni za liječenje s njim povezanih poremećaja
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
KR20110086132A (ko) 2008-11-07 2011-07-27 인슐린 메디컬 엘티디 약물 전달 장치 및 방법
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8565107B2 (en) 2010-09-24 2013-10-22 Hand Held Products, Inc. Terminal configurable for use within an unknown regulatory domain
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為5-ht2a血清素受體的二芳基及芳基雜芳基脲衍生物
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
LT4299135T (lt) 2019-06-18 2025-09-10 Pfizer Inc. Benzizoksazolo sulfonamido dariniai
PT4082616T (pt) * 2019-12-24 2025-12-02 Sumitomo Pharma Co Ltd Derivado de amida ácida alifática
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331541A (en) * 1965-06-07 1967-07-18 Bell & Howell Co Sprocketless projector
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DK60593D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
FR2742052B1 (fr) 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
AU3261097A (en) 1996-06-21 1998-01-14 Glaxo Group Limited Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
DE69829317T2 (de) * 1997-12-25 2006-04-06 Meiji Seika Kaisha Ltd. Tetrahydrobenzindol-derivate
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ES2165274B1 (es) * 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
ES2317116T3 (es) 2001-02-16 2009-04-16 Aventis Pharmaceuticals Inc. Derivados de carbonilos sustituidos heterociclicos y su uso como ligandos del receptor de dopamina d3.
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
ES2201899B1 (es) * 2002-04-01 2005-06-01 Almirall Prodesfarma, S.A. Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos.
CN101208314B (zh) * 2005-04-26 2010-12-08 海普尼昂公司 苯并异*唑哌嗪化合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2008539267A5 (enExample)
JP2008539268A5 (enExample)
JP2010500293A5 (enExample)
JP2010529118A5 (enExample)
JP2015505296A5 (enExample)
JP2012532874A5 (enExample)
JP2006143751A5 (enExample)
JP2010077141A5 (enExample)
JP2010509379A5 (enExample)
JP2010524932A5 (enExample)
JP2013519675A5 (enExample)
JP2014518266A5 (enExample)
JP2013525444A5 (enExample)
JP2009502743A5 (enExample)
JP2009507909A5 (enExample)
JP2010540509A5 (enExample)
JP2011523412A5 (enExample)
JP2013508279A5 (enExample)
WO2008154083A3 (en) Compounds, compositions and methods for the treatment of synucleinopathies
JP2014530900A5 (enExample)
JP2010504343A5 (enExample)
JP2008513510A5 (enExample)
JP2013514980A5 (enExample)
JP2010518061A5 (enExample)
JP2011505356A5 (enExample)